All In Biotech

Drug Trial Radar · NCT01127750

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 in Patients With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Feb 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,417

Actual

Start

May 2010

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
May 21, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • FTY720Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability profile of FTY720 in patients with relapsing forms of MSTime frame: 4 months

Locations

289 sites in 23 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Box Hill, Australia

  • Novartis Investigative Site

    Heidelberg, Australia

  • Novartis Investigative Site

    Kogarah, Australia

  • Novartis Investigative Site

    Liverpool, Australia

  • Novartis Investigative Site

    Woodville South, Australia

  • Novartis Investigational Site

    Linz, Austria

  • Novartis Investigational Site

    Vienna, Austria

  • Novartis Investigational Site

    Vienna, Austria

  • Novartis Investigational Site

    Bruges, Belgium

  • Novartis Investigational Site

    Brussels, Belgium

  • Novartis Investigational Site

    Brussels, Belgium

  • Novartis Investigational Site

    Charleroi, Belgium

  • Novartis Investigational Site

    Leuven, Belgium

  • Novartis Investigational Site

    Melsbroek, Belgium

  • Novartis Investigational Site

    Overpelt, Belgium

  • Novartis Investigational Site

    Sijsele, Belgium

  • Novartis Investigational Site

    Tinlot, Belgium

  • Novartis Investigational Site

    Wilrijk, Belgium

  • Novartis Investigational Site

    Montreal, Canada

  • Novartis Investigational Site

    Québec, Canada

  • Novartis Investigational Site

    Victoria, Canada

  • Novartis Investigational Site

    Prague, Czechia

  • Novartis Investigational Site

    Teplice, Czechia

  • Novartis Investigational Site

    Aarhus, Denmark

  • Novartis Investigational Site

    Copenhagen, Denmark

  • Novartis Investigational Site

    Helsinki, Finland

  • Novartis Investigational Site

    Turku, Finland

  • Novartis Investigational Site

    Aachen, Germany

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigational Site

    Aalen, Germany

  • Novartis Investigational Site

    Abensberg, Germany

  • Novartis Investigational Site

    Achim, Germany

  • Novartis Investigational Site

    Alzenau in Unterfranken, Germany

  • Novartis Investigational Site

    Aschaffenburg, Germany

  • Novartis Investigational Site

    Attenberg, Germany

  • Novartis Investigational Site

    Augsburg, Germany

  • Novartis Investigational Site

    Bad Honnef, Germany

  • Novartis Investigational Site

    Bad Krozingen, Germany

  • Novartis Investigative Site

    Bad Mergentheim, Germany

  • Novartis Investigational Site

    Bad Neustadt / Saale, Germany

Showing 40 of 289 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.